Gewählte Publikation:
Schwinger, W; Urban, C; Lackner, H; Mache, C.
Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor.
Ann Hematol. 1993; 66(4):181-184
Doi: 10.1007/BF01703233
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
-
Schwinger Wolfgang
- Co-Autor*innen der Med Uni Graz
-
Lackner Herwig
-
Mache Christoph
-
Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Severe aplastic anemia (SAA) has been related in most cases to underlying autoimmune conditions. Various immunosuppressive regimens have been recommended in the absence of an HLA-identical bone marrow donor. Prednisolone, antithymocyte globulin, and cyclosporin A have been shown to be effective. This report describes the successful treatment of a 23-year-old woman suffering from severe aplastic anemia who had become multiresistant against previously administered immunosuppressive agents, using a monoclonal IL-2-receptor blocking antibody. The patient responded within 4 weeks. The time to the next relapse was 8 months; however, another remission with a second course of horse-antithymocyte globulin was achieved and has been maintained for 27 months to date with low doses of cyclosporin A. Although this is an anecdotical report, IL-2-receptor blockade using a monoclonal antibody might be considered as a further alternative in multi-resistant SAA, perhaps increasing the susceptibility to further immunosuppressive trials.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adult -
-
Anemia, Aplastic - blood
-
Antibodies, Monoclonal - therapeutic use
-
Cyclosporine - therapeutic use
-
Female - therapeutic use
-
Humans - therapeutic use
-
Injections, Intravenous - therapeutic use
-
Methylprednisolone - therapeutic use
-
Receptors, Interleukin-2 - immunology
-
Recurrence - immunology
- Find related publications in this database (Keywords)
-
Aplastic Anemia
-
Immunosuppressive Therapy
-
IL-2-Receptor Antibody